Japan Approves First Stem-Cell Therapies for Parkinson’s and Heart Failure

Japan has approved groundbreaking stem-cell based treatments for Parkinson’s disease and severe heart failure, marking a major milestone in regenerative medicine. The country’s health authorities have granted approval for therapies that use induced pluripotent stem (iPS) cells, which could soon become the world’s first commercially available medical products based on this technology.

Parkinson’s Treatment Approved

Pharmaceutical company Sumitomo Pharma received regulatory approval to manufacture and sell Amchepry, a treatment for Parkinson’s disease. The therapy involves transplanting stem cells into a patient’s brain to replace damaged neurons responsible for producing dopamine.

Clinical trials led by researchers at Kyoto University showed promising results. The study involved seven Parkinson’s patients aged 50–69, each receiving five million or ten million stem-cell derived precursors implanted into both sides of the brain. These cells were developed from iPS cells obtained from healthy donors and were programmed to become dopamine-producing neurons, which are depleted in Parkinson’s patients.

Heart Failure Therapy

Japan’s health ministry also approved ReHeart, a therapy developed by medical startup Cuorips. The treatment uses heart muscle sheets grown from stem cells, which are placed on the heart to promote the formation of new blood vessels and restore cardiac function in patients with severe heart failure.

Role of iPS Cell Technology

The therapies rely on Induced Pluripotent Stem Cells (iPSCs)—adult cells such as skin or blood cells that are reprogrammed into an embryonic-like pluripotent state using specific transcription factors. These cells can self-renew and differentiate into almost any cell type in the human body, making them highly valuable for regenerative medicine.

iPS cells can also be made from a patient’s own cells, minimizing the chance of immune rejection.

The technology was pioneered by Japanese scientist Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine 2012 for his discovery of iPS cells.

About Parkinson’s Disease

Parkinson’s disease is a chronic and degenerative neurological disorder that affects the body’s motor system. Patients often experience tremors, stiffness, and difficulty with movement, primarily due to the loss of dopamine-producing neurons in the brain.

Global Significance

The newly approved therapies could reach patients as early as this summer, positioning Japan at the forefront of stem-cell based regenerative treatments and potentially transforming treatment approaches for neurodegenerative and cardiovascular diseases worldwide.

Source: SCIENCE